Ketorolac Mylan (Ketorolac Trometamol)

Ketorolac Trometamol blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, preventing the formation of prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, the drug lessens peripheral sensitisation of pain receptors and diminishes the inflammatory response.

The specific dose and duration of Ketorolac Mylan are determined by the prescribing clinician based on the patient’s condition, age, renal function, and other factors. The medication is intended for short‑term use, and the prescriber will set the appropriate regimen.

Safety data for Ketorolac Trometamol in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Ketorolac Mylan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Ketorolac is a potent NSAID with analgesic efficacy comparable to moderate‑dose opioids for short‑term use, whereas many other NSAIDs are primarily used for mild to moderate pain. Its stronger COX inhibition offers rapid pain relief but also carries a higher risk of gastrointestinal and renal adverse effects, requiring careful patient selection.

Ketorolac Mylan tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Ketorolac Mylan is taken orally, usually with a full glass of water. It may be taken with or without food, but patients with a history of stomach upset may benefit from taking it with meals to minimise gastrointestinal irritation.

The most serious risks include gastrointestinal bleeding, ulceration or perforation, severe renal impairment, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored for signs of bleeding, reduced urine output, or allergic symptoms, and the drug should be stopped immediately if these occur.

Ketorolac Mylan is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active peptic ulcer disease, severe renal impairment, and those who have had recent coronary artery bypass graft surgery. It should also be avoided in pregnancy, especially in the third trimester, unless clearly indicated by a physician.